Bioavailability of diclofenac potassium at low doses

British Journal of Clinical Pharmacology

Volumn 59, Issue 1, 2005, Pages 80-84

  Hinz, Burkhard ^a   Chevts, Julia ^a   Renner, Bertold ^a   Wuttke, Henrike ^a   Rau, Thomas ^a   Schmidt, Andreas ^a   Szelenyi, Istvan ^a   Brune, Kay ^a   Werner, Ulrike ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Bioavailability; Diclofenac; Pharmacokinetics; Potassium salt

Indexed keywords

DICLOFENAC POTASSIUM;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG METABOLISM; FEMALE; FIRST PASS EFFECT; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; FEMALE; HUMANS; MALE;

EID: 11144252287     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02226.x     Document Type: Article

References (18)

1. Hinz B, Rau T, Auge D et al. Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther 2003; 74: 222-35.
2. Brune K, Lanz R. Pharmacokinetics of non-steroidal anti-inflammatory drugs. In Handbook of Inflammation, Vol. 5, The Pharmacology of Inflammation, eds Bonta IL, Bray MA, Parnham MJ. Amsterdam: Elsevier, 1985; 413-49.
3. John VA. The pharmacokinetics and metabolism of diclofenac sodium (Voltarol) in animals and man. Rheumatol Rehabil Suppl 1979; 2: 22-37.
4. Willis JV, Kendall MJ, Flinn RM, Thornhill DP, Welling PG. The pharmacokinetics of diclofenac sodium following intravenous and oral administration. Eur J Clin Pharmacol 1979; 16: 405-10.
5. McNeely W, Goa KL. Diclofenac-potassium in migraine: a review. Drugs 1999; 57: 991-1003.
6. Marzo A, Dal Bo L, Verga F et al. Pharmacokinetics of diclofenac after oral administration of its potassium salt in sachet and tablet formulations. Arzneimittelforschung 2000; 50: 43-7.
7. Reiner V, Reiner A, Reiner G, Conti M. Increased absorption rate of diclofenac from fast acting formulations containing its potassium salt. Arzneimittelforschung 2001; 51: 885-90.
8. Olson NZ, Sunshine A, Zighelboim I, DeCastro A. Onset and duration of analgesia of diclofenac potassium in the treatment of postepisiotomy pain. Am J Ther 1997; 4: 239-46.
9. Morant J, Ruppaner H, eds. Voltaren dolo. In Compendium Suisse Des Medicaments. Basel: Dokumed, 2002; 2900-1.
10. Grebe W, Ionescu E, Gold MS, Liu JM, Frank WO. A multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled, parallel-group comparison of diclofenac-K and ibuprofen for the treatment of adults with influenza-like symptoms. Clin Ther 2003; 25: 444-58.
11. Sioufi A, Stierlin H, Schweizer A et al. Recent findings concerning clinically relevant pharmacokinetics of diclofenac sodium. In Voltaren - New Findings, eds Käss EH. Bern, Stuttgart, Vienna: Huber Publishers, 1982; 19-30.
12. Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls. Clin Pharmacokinet 1997; 33: 184-213.
13. Shand DG. Pharmacokinetics of propranolol: a review. Postgrad Med J 1976; 52 (Suppl. 4): 22-5.
14. Mackichan JJ, Pyszczynski DR, Jusko WJ. Dose-dependent disposition of oral propranolol in normal subjects. Biopharm Drug Dispos 1980; 1: 159-66.
15. Shah VP, Midha KK, Dighe S et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet 1991; 16: 249-55.
16. Shim CK, Jung BH. Noncontribution of entereohepatic recycling to multiple plasma peaks of acetaminophen in rats. Int J Pharm 1992; 83: 257-62.
17. Nation RL, Sansom LN. Bioequivalence requirements for generic products. Pharmacol Ther 1994; 62: 41-55.
18. Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-17.